Intec Pharma Ltd. | Mutual Funds

Mutual Funds that own Intec Pharma Ltd.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
801,252
2.41%
0
1.02%
05/31/2018
Clal Exposure to Commodities
278,000
0.84%
-2,403
1.57%
06/28/2018
Government Pension Fund - Global (The)
206,192
0.62%
206,192
0%
12/31/2017
U - Bank 20/80
191,038
0.56%
-8,962
2%
06/28/2018
Clal Equity
159,481
0.48%
0
1.41%
06/28/2018
130,000
0.39%
0
0.4%
05/31/2018
107,761
0.32%
0
1.82%
09/05/2018
54,000
0.16%
0
0.15%
05/31/2018
53,189
0.16%
227
1.07%
05/31/2018
Modus Bonds 90/10
50,000
0.15%
-7,298
1.01%
06/28/2018

About Intec Pharma

View Profile
Address
RMPE Building
Jerusalem JM 9777512
Israel
Employees -
Website http://www.intecpharma.com
Updated 07/08/2019
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which focuses on developing drugs based on its proprietary Accordion Pill platform technology. Its product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients; Accordion Pill Zaleplon, which is being developed for the treatment of insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug which induces ulcers; and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol and tetrahydrocannabinol, which is being developed for various indications including low back neuropathic pain and fibromyalgia. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.